Boston, MA -- (ReleaseWire) -- 10/30/2012 -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.
- Patient-based forecasts for Aveo's lead candidate, tivozanib, supported by key opinion leader research
- Assessment of Aveo's corporate strategy, operating performance, and earlier-stage pipeline
Aveo's lead candidate is tivozanib, a small molecule oral angiogenesis inhibitor. Its primary indication (for which it plans to seek US approval) is in metastatic renal cell carcinoma, but Aveo is also developing the drug for colorectal cancer and breast cancer.
Aveo plans to submit a New Drug Application for tivozanib in the third quarter of 2012, while commercialization partner Astellas will submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2012.
View Full Report Details and Table of Contents
Reasons to Get this Report
- Evaluate the potential of Aveo's Phase III oncology product, tovozanib
- Assess the potential of the company's earlier-stage pipeline of novel antibodies
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- AVEO Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
- AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- AVEO Pharmaceuticals, Inc. - Product Pipeline Review - Q2 2011
- MAP Pharmaceuticals: PharmaVitae Report
- Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Ariad Pharmaceuticals: PharmaVitae Report
- AVEO Pharmaceuticals, Inc. (AVEO) - Financial and Strategic SWOT Analysis Review
- OSI Pharmaceuticals, Inc. (OSIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Regeneron Pharmaceuticals, Inc.: PharmaVitae Report
- Amylin Pharmaceuticals, Inc.: PharmaVitae Report